Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N et al (2017) Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317(23):2402–2416

Article  CAS  PubMed  Google Scholar 

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM et al (2018) Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer. Br J Cancer 119(4):408–418

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O et al (2016) Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Oncol Biol Phys 94(5):1061–1072

Article  PubMed  Google Scholar 

Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B et al (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368(11):987–998

Article  CAS  PubMed  Google Scholar 

Jacobse JN, Duane FK, Boekel NB, Schaapveld M, Hauptmann M, Hooning MJ, Seynaeve CM, Baaijens MHA, Gietema JA, Darby SC et al (2019) Radiation dose-response for risk of myocardial infarction in breast cancer survivors. Int J Radiat Oncol Biol Phys 103(3):595–604

Article  PubMed  PubMed Central  Google Scholar 

Elliott P (2006) Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol 33(3 Suppl 8):S2-7

Article  CAS  PubMed  Google Scholar 

Lanza O, Ferrera A, Reale S, Solfanelli G, Petrungaro M, Tini Melato G, Volpe M, Battistoni A (2022) New insights on the toxicity on heart and vessels of breast cancer therapies. Med Sci (Basel) 10(2):27

CAS  PubMed  Google Scholar 

Quintero-Martinez JA, Cordova-Madera SN, Villarraga HR (2021) Radiation-induced heart disease. J Clin Med 11(1):146

Article  PubMed  PubMed Central  Google Scholar 

Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Boriani G, Cardinale D, Cordoba R, Cosyns B et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Eur Heart J 43(41):4229–4361

Article  PubMed  Google Scholar 

Zhang J, Powell SN (2005) The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res : MCR 3(10):531–539

Article  CAS  PubMed  Google Scholar 

Takaoka M, Miki Y (2018) BRCA1 gene: function and deficiency. Int J Clin Oncol 23(1):36–44

Article  CAS  PubMed  Google Scholar 

Foulkes WD, Shuen AY (2013) In brief: BRCA1 and BRCA2. J Pathol 230(4):347–349

Article  CAS  PubMed  Google Scholar 

Savage KI, Harkin DP (2015) BRCA1, a ‘complex’ protein involved in the maintenance of genomic stability. FEBS J 282(4):630–646

Article  CAS  PubMed  Google Scholar 

Bhatia V, Barroso SI, Garcia-Rubio ML, Tumini E, Herrera-Moyano E, Aguilera A (2014) BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2. Nature 511(7509):362–365

Article  CAS  PubMed  Google Scholar 

Fridlich R, Annamalai D, Roy R, Bernheim G, Powell SN (2015) BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication. DNA Repair 30:11–20

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, Xu J, Goldberg ID, Jaiswal AK, Rosen EM (2004) BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Can Res 64(21):7893–7909

Article  CAS  Google Scholar 

Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, Cao L, Rovira II, Pan Y, Brezden-Masley C et al (2011) BRCA1 is an essential regulator of heart function and survival following myocardial infarction. Nat Commun 2:593

Article  PubMed  Google Scholar 

Singh S, Nguyen H, Michels D, Bazinet H, Matkar PN, Liu Z, Esene L, Adam M, Bugyei-Twum A, Mebrahtu E et al (2020) BReast CAncer susceptibility gene 2 deficiency exacerbates oxidized LDL-induced DNA damage and endothelial apoptosis. Physiol Rep 8(13):e14481

Article  CAS  PubMed  PubMed Central  Google Scholar 

Singh KK, Shukla PC, Quan A, Desjardins JF, Lovren F, Pan Y, Garg V, Gosal S, Garg A, Szmitko PE et al (2012) BRCA2 protein deficiency exaggerates doxorubicin-induced cardiomyocyte apoptosis and cardiac failure. J Biol Chem 287(9):6604–6614

Article  CAS  PubMed  Google Scholar 

Mai PL, Chatterjee N, Hartge P, Tucker M, Brody L, Struewing JP, Wacholder S (2009) Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. PLoS ONE 4(3):e4812

Article  PubMed  PubMed Central  Google Scholar 

van Westerop LL, Arts-de Jong M, Hoogerbrugge N, de Hullu JA, Maas AH (2016) Cardiovascular risk of BRCA1/2 mutation carriers: a review. Maturitas 91:135–139

Article  PubMed  Google Scholar 

Demissei BG, Lv W, Wilcox NS, Sheline K, Smith AM, Sturgeon KM, McDermott-Roe C, Musunuru K, Lefebvre B, Domchek SM et al (2022) BRCA1/2 mutations and cardiovascular function in breast cancer survivors. Front Cardiovasc Med 9:833171

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barac A, Lynce F, Smith KL, Mete M, Shara NM, Asch FM, Nardacci MP, Wray L, Herbolsheimer P, Nunes RA et al (2016) Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. Breast Cancer Res Treat 155(2):285–293

Article  CAS  PubMed  Google Scholar 

Pearson EJ, Nair A, Daoud Y, Blum JL (2017) The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy. Breast Cancer Res Treat 162(1):59–67

Article  CAS  PubMed  Google Scholar 

Sajjad M, Fradley M, Sun W, Kim J, Zhao X, Pal T, Ismail-Khan R (2017) An exploratory study to determine whether BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity. Genes 8(2):59

Article  PubMed  PubMed Central  Google Scholar 

Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, Taylor CW, van Leeuwen FE (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99(5):365–375

Article  PubMed  Google Scholar 

Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, Tilanus-Linthorst MM, Koppert LB, Obdeijn IM, van Deurzen CH, Collee JM, Seynaeve C, Hooning MJ (2013) Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Annal Oncol 24(8):2029–2035

Article  CAS  Google Scholar 

Drooger J, Akdeniz D, Pignol JP, Koppert LB, McCool D, Seynaeve CM, Hooning MJ, Jager A (2015) Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age. Breast Cancer Res Treat 154(1):171–180

Article  CAS  PubMed  PubMed Central  Google Scholar 

van den Broek AJ, Van’t Veer LJ, Hooning MJ, Cornelissen S, Broeks A, Rutgers EJ, Smit VT, Cornelisse CJ, Van Beek M, et al (2016) Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers. J Clinl Oncol 34(5):409–418

Article  Google Scholar 

van den Broek AJ, de Ruiter K, van ’t Veer LJ, Tollenaar RA, van Leeuwen FE, Verhoef S, Schmidt MK, (2015) Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. European J Human Gen EJHG 23(5):588–595

Article